The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1322
Dronedarone (Multaq) for Atrial Fibrillation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Dronedarone (Multaq – Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but has considerable toxicity.1

PHARMACOLOGY — Dronedarone is a non-iodinated analog of amiodarone. It is also significantly less lipophilic than amiodarone, resulting in a substantially smaller volume of distribution and a much shorter elimination half-life. Like amiodarone, dronedarone blocks sodium, potassium and calcium channels and also has alpha- and beta-blocking properties.

CLINICAL STUDIES — Four published clinical trials comparing dronedarone with placebo are summarized in Table 2. The fifth, DIONYSOS, which compared dronedarone to amiodarone, has only been presented at a scientific session and the data in the table were obtained from a ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Dronedarone (Multaq) for Atrial Fibrillation
Article code: 1322b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian